Patients versus Populations Risk Enhancements versus Age Criteria

Christine M. Albert, MD, MPH

Director, Center for Arrhythmia Prevention, Brigham and Women's Hospital Professor of Medicine, Harvard Medical School



BRIGHAM AND WOMEN'S HOSPITAL Heart & Vascular Center



Screening: AF Prevalence



Prevalence of AF in the population impacts the effectiveness of screening





• False Positives: 1). Expense of monitoring 2). Exposure to risks of AOC without benefit

Office-Based Screening for Atrial Fibrillation

Table 3 | Prevalence and detection rate of new cases by age at start of study and sex. Figures are numbers (percentages)

Group	Men			Women			
	65-74	75-84	≥85	65-74	75-84	≥85	Total
Baseline prevale	ence						
Control	74/1216 (6.1)	84/703 (11.9)	25/156 (16.0)	44/1378 (3.2)	106/1050(10.1)	56/420 (13.3)	389/4923 (7.9)
Opportunistic	70/1304 (5.4)	63/650 (9.7)	24/148 (16.2)	48/1448 (3.3)	91/1005 (9.1)	44/375 (11.7)	340/4930 (6.9)
Systematic	69/1318 (5.2)	67/647 (10.4)	15/154 (9.7)	68/1391 (4.9)	70/1022 (6.8)	50/396 (12.6)	339/4928 (6.9)
12 month preva	lence						
Control	81/1213 (6.7)	91/699 (13.0)	27/151 (17.9)	55/1377 (4.0)	122/1044(11.7)	60/418 (14.4)	436/4902 (8.9)
Opportunistic	90/1303 (6.9)	77/647 (11.9)	28/148 (18.9)	59/1443 (4.1)	109/1001 (10.9)	52/373 (13.9)	415/4915 (8.4)
Systematic	90/1312 (6.9)	82/643 (12.8)	23/154 (14.9)	77/1387 (5.6)	88/1012 (8.7)	53/398 (13.5)	413/4906 (8.4)
12 month new c	ase detection						
Control	7/1139 (0.6)	7/615 (1.1)	2/126 (1.6)	11/1333 (0.8)	16/938 (1.7)	4/362 (1.1)	47/4513 (1.0)
Opportunistic	20/1233 (1.6)	14/584 (2.4)	4/124 (3.2)	11/1395 (0.8)	18/910 (2.0)	8/329 (2.4)	75/4575 (1.6)
Systematic	21/1243 (1.7)	15/576 (2.6)	8/139 (5.8)	9/1319 (0.7)	18/942 (1.9)	3/343 (0.9)	74/4562 (1.6)

Fitzmaurice et al. BMJ 2007

Mass Screening for Atrial Fibrillation in 75 Year Olds The STROKESTOP Study





- Add > 1 stroke risk factor to 75+: 7.4% have undetected AF.
- Cryptogenic Stroke: 16% reported with 30 day monitoring

Svennberg E et al. *Circulation* 2015;131:2176-84 Engdahl J et al. *Circulation* 2013: 127:930-937 Gladstone DJ et al. *NEJM*; 2014; 370:2467-2477

(87.67%)

Enhancing Prevalence in Screened Populations



- CHA2DS2-VASc:
 - Age, Stroke, Female Sex, HTN, Vascular disease, HF, diabetes.

- AF Risk Scores:
 - <u>CHARGE</u>: Age, male sex, white race, weight, height,
 SBP, DBP, antihypertensive, Diabetes, CVD, MI, Heart
 Failure
 - <u>WHS (Women)</u>: Age, Weight, Height, SBP, alcohol, smoking.

60 p=0.37 50 p=0.003 40 a 20 p=0.004 p=0.004 Newly diagnosed AF, n=218 No AF, n=6289

p=0.31

Stoker 11 A. op

beres,

Female sex, lower weight, and absence of vascular disease were significantly associated with no detection of AF.

CHA2DS2-VASc was not associated with AF detection

Svennberg E et al. Circulation 2015;131:2176-84

Characteristics of Patients with SCAF Detected

10

0

p=0.31

CH4, 0/2

